H.C. Wainwright raised the firm’s price target on MannKind to $7.50 from $7 and keeps a Buy rating on the shares post the Q2 report. The analyst sees “meaningful upside” from Tyvaso DPI with “upside optionality” from potential label expansion and the company’s internal orphan lung pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MNKD:
- Biotech Alert: Searches spiking for these stocks today
- MannKind Corporation Reports 2023 Second Quarter Financial Results
- MNKD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
- MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
